Development and Clinical Translation of immunoPET Imaging Probes for Breast Cancer
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY
The aim of this study is to establish and optimize the Trop2/HER2-targeted PET/CT imaging method, and its physiological and pathological distribution characteristics, on the basis of which the diagnostic efficacy of the above imaging agents in breast cancer will be evaluated.
Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• Aged 18-75 years old and of female gender；
• Histologically confirmed diagnosis of breast cancer or suspected breast cancer by diagnostic imaging;
• Capable of giving signed informed consent, including compliance with the requirements and restrictions listed in the informed consent form (ICF) and this protocol.
Locations
Other Locations
China
Renji Hospital, School of Medicine, Shanghai Jiao Tong University
RECRUITING
Shanghai
Contact Information
Primary
Weijun Wei, Ph.D. & M.D.
wwei@shsmu.edu.cn
15000083153
Backup
Wenzhi Jia, Ph.D. & M.D.
jwzdata@126.com
18317076979
Time Frame
Start Date: 2024-09-21
Estimated Completion Date: 2026-11
Participants
Target number of participants: 200
Treatments
Experimental: Trop2/HER2-targeted immunoPET imaging
Enrolled patients will undergo a Trop2/HER2-targeted immunoPET/CT scanning.
Related Therapeutic Areas
Sponsors
Leads: RenJi Hospital